Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

78.00 -9.01 (-10.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
MarketBeat Week in Review – 10/21- 10/25
Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Monopar Therapeutics Shares Friday? ↗
Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease. 
Via Benzinga
News headline image
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. 
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. 
Via Benzinga
Topics Stocks
News headline image
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder ↗
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder. 
Via Benzinga
News headline image
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today ↗
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans. 
Via Benzinga
News headline image
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 ↗
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗
 
Via Benzinga
News headline image
Monopar and NorthStar Amend & Extend Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely ↗
Penny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why the SEC has a warning about them too. 
Via InvestorPlace
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.